<VariationArchive RecordType="classified" VariationID="7255" VariationName="NM_005251.3(FOXC2):c.588dup (p.Thr197fs)" VariationType="Duplication" Accession="VCV000007255" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-07-29" DateCreated="2015-10-11" MostRecentSubmission="2015-10-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="22294" VariationID="7255">
      <GeneList>
        <Gene Symbol="FOXC2" FullName="forkhead box C2" GeneID="2303" HGNC_ID="HGNC:3801" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16q24.1</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="86566829" stop="86569728" display_start="86566829" display_stop="86569728" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="86600856" stop="86602538" display_start="86600856" display_stop="86602538" Strand="+" />
          </Location>
          <OMIM>602402</OMIM>
          <Haploinsufficiency last_evaluated="2013-11-26" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXC2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2013-11-26" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FOXC2">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_005251.3(FOXC2):c.588dup (p.Thr197fs)</Name>
      <CanonicalSPDI>NC_000016.10:86567921:CC:CCC</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>16q24.1</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="86567921" stop="86567922" display_start="86567921" display_stop="86567922" variantLength="1" positionVCF="86567921" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="86601527" stop="86601528" display_start="86601527" display_stop="86601528" variantLength="1" positionVCF="86601527" referenceAlleleVCF="G" alternateAlleleVCF="GC" />
      </Location>
      <ProteinChange>T197fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1292" sequenceAccession="LRG_1292">
            <Expression>LRG_1292:g.6095dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1292t1" sequenceAccession="LRG_1292t1">
            <Expression>LRG_1292t1:c.588dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1292p1" sequenceAccession="LRG_1292p1" change="p.Thr197fs">
            <Expression>LRG_1292p1:p.Thr197fs</Expression>
          </ProteinExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.86567923dup" Assembly="GRCh38">
            <Expression>NC_000016.10:g.86567923dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.86601529dup" Assembly="GRCh37">
            <Expression>NC_000016.9:g.86601529dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_012025.2" sequenceAccession="NG_012025" sequenceVersion="2" change="g.6095dup">
            <Expression>NG_012025.2:g.6095dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_005251.3" sequenceAccession="NM_005251" sequenceVersion="3" change="c.588dup" MANESelect="true">
            <Expression>NM_005251.3:c.588dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_005242.1" sequenceAccession="NP_005242" sequenceVersion="1" change="p.Thr197fs">
            <Expression>NP_005242.1:p.Thr197fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="FOXC2_000014" DB="LOVD 3" />
        <XRef Type="Allelic variant" ID="602402.0007" DB="OMIM" />
        <XRef Type="rs" ID="1567571345" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_005251.3(FOXC2):c.588dup (p.Thr197fs) AND Distichiasis-lymphedema syndrome" Accession="RCV000007677" Version="3">
        <ClassifiedConditionList TraitSetID="1971">
          <ClassifiedCondition DB="MedGen" ID="C0265345">Distichiasis-lymphedema syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="2008-03-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2008-03-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2015-10-11" MostRecentSubmission="2015-10-11">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">11371511</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18197197</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1971" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="2577" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Lymphedema with distichiasis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hereditary lymphedema-distichiasis syndrome (subtype)</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Distichiasis-lymphedema syndrome</ElementValue>
                <XRef ID="Lymphedema+distichiasis+syndrome/4357" DB="Genetic Alliance" />
                <XRef ID="8634009" DB="SNOMED CT" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="333" />
                <XRef ID="333" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Lymphedema-distichiasis syndrome (referred to as LDS in this GeneReview) is characterized by lower-limb lymphedema, and distichiasis (aberrant eyelashes ranging from a full set of extra eyelashes to a single hair). Lymphedema typically appears in late childhood or puberty, is confined to the lower limbs with or without involvement of the external genitalia, and is often asymmetric; severity varies within families. Males develop edema at an earlier age and have more problems with cellulitis than females. Distichiasis, which may be present at birth, is observed in 94% of affected individuals. About 75% of affected individuals have ocular findings including corneal irritation, recurrent conjunctivitis, and photophobia; other common findings include varicose veins and ptosis.</Attribute>
                <XRef ID="NBK1457" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301630</ID>
                <ID Source="BookShelf">NBK1457</ID>
              </Citation>
              <XRef ID="33001" DB="Orphanet" />
              <XRef ID="C0265345" DB="MedGen" />
              <XRef ID="MONDO:0007922" DB="MONDO" />
              <XRef Type="MIM" ID="153400" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="27878" SubmissionDate="2019-01-02" DateLastUpdated="2015-10-11" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="602402.0007_LYMPHEDEMA-DISTICHIASIS SYNDROME" title="FOXC2, 1-BP INS, 589C_LYMPHEDEMA-DISTICHIASIS SYNDROME" />
        <ClinVarAccession Accession="SCV000027878" DateUpdated="2015-10-11" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2008-03-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">In a family with lymphedema-distichiasis syndrome (LPHDST; 153400), Finegold et al. (2001) identified a 1-bp insertion (5890insC) in the FOXC2 gene, resulting in a frameshift with premature termination at amino acid 463. Age of onset of lymphedema was after puberty. One patient had distichiasis, and another had a cleft palate.</Attribute>
              <Citation>
                <ID Source="PubMed">11371511</ID>
              </Citation>
              <XRef DB="OMIM" ID="153400" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Finegold et al. (2001) identified the same mutation in affected members of another family with LPHDST. Three of 7 affected family members also exhibited ptosis, and 3 also had yellow nails, thus suggesting phenotypic overlap between lymphedema-distichiasis syndrome and lymphedema-yellow nail syndrome (153300).</Attribute>
              <Citation>
                <ID Source="PubMed">11371511</ID>
              </Citation>
              <XRef DB="OMIM" ID="153300" Type="MIM" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="Description">Rezaie et al. (2008) disputed some of the diagnoses of Finegold et al. (2001), and noted that yellow discoloration of the nails is not uncommon with lymphedema, but does not necessarily indicate a diagnosis of so-called 'yellow nail syndrome,' in which the nail changes are very specific. In yellow nail syndrome, the nail plate is yellow and over-curved but it remains translucent and smooth. By contrast, in lymphedema not associated with yellow nail syndrome, the nails become thickened, rough and opaque. Associated features such as chronic sinusitis, bronchiectasis or pleural effusion are often essential for a diagnosis of yellow nail syndrome. Indeed, Finegold et al. (2001) found no FOXC2 mutations in 4 families with lymphedema and yellow nail syndrome. Rezaie et al. (2008) concluded that the families with the 589insC mutation were most consistent with lymphedema-distichiasis syndrome.</Attribute>
              <Citation>
                <ID Source="PubMed">18197197</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">11371511</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FOXC2" />
          </GeneList>
          <Name>FOXC2, 1-BP INS, 589C</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, 589C</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="602402.0007" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">LYMPHEDEMA-DISTICHIASIS SYNDROME</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="27878" TraitType="Disease" MappingType="Name" MappingValue="LYMPHEDEMA-DISTICHIASIS SYNDROME" MappingRef="Preferred">
        <MedGen CUI="C0265345" Name="Distichiasis-lymphedema syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

